Product development strategy

 Enzymatica’s product development strategy has the following priorities

  1. Optimize ColdZyme (production, technical documentation, market access outside the EU, clinical studies, new patents, etc.).
  2. Strengthen and expand existing claims through additional studies.
  3. Formulate new ColdZyme versions (“line extensions”) to expand the product offering and to increase shelf exposure at the sales location.
  4. Explore new indications with the same formulation and function, which requires minimal lead time for product development (existing storage studies, toxicity tests, etc., can be used).
  5. Develop new product formulations for use within the file of ear, nose and throat (ENT).
  6. Develop new products for completely new indications.


Enzymatica cares about your privacy and processes your personal data in accordance with the EU’s General Data Protection Regulation. For more information about how we handle your personal information, and what rights you have, please refer to our personal data processing document here.